What You Should Know:

您应该知道：

– Pelvital USA, Inc., a leading women’s health innovator, has announced the successful closing of an oversubscribed $5M seed-plus funding round. The investment round was led by Boomerang Ventures with new investors including Pier 70 Ventures, Life Science Angels, Tech Coast Angels Orange County, and Blue Pacific Fund..

–领先的女性健康创新者骨盆美国公司（Pelvital USA，Inc.）宣布，一轮超额认购的500万美元seed plus融资成功结束。这轮投资由Boomerang Ventures牵头，新投资者包括Pier 70 Ventures、Life Science Angels、Tech Coast Angels Orange County和Blue Pacific Fund。

– This additional $2.32M funding will significantly accelerate the commercialization of Flyte, their novel treatment for stress urinary incontinence (SUI).

–这笔额外的232万美元资金将大大加速Flyte的商业化，Flyte是一种治疗压力性尿失禁（SUI）的新型疗法。

Flyte: A Game-Changer for Women with SUI

Flyte：SUI女性的游戏规则改变者

Flyte is a revolutionary, FDA-cleared, and clinically proven treatment designed to address SUI and strengthen pelvic floor muscles. This accessible and easy-to-use solution offers women a non-invasive option to manage this common condition.  The typical treatment regimen involves using the device for only five minutes a day, for six weeks.  While FDA-cleared for over-the-counter use, Flyte is often prescribed by clinicians, ensuring optimal patient care and guidance..

Flyte是一种革命性的，FDA批准的，临床证明的治疗方法，旨在解决SUI并增强盆底肌肉。这种易于获取且易于使用的解决方案为女性提供了一种非侵入性的选择来管理这种常见疾病。典型的治疗方案是每天只使用该设备五分钟，持续六周。虽然FDA批准非处方使用，但Flyte通常由临床医生开具，以确保最佳的患者护理和指导。

Clinically Validated Efficacy and Durability

临床验证的功效和耐久性

Two published clinical trials have demonstrably validated Flyte’s safety, effectiveness, and long-lasting treatment benefits for women with SUI. A recent study published in Therapeutic Advances in Urology revealed that 71% of participants achieved dry or near dry status after using Flyte for just 2-12 weeks, as evidenced by a reduction in 24-hour pad weight..

两项已发表的临床试验已证明Flyte对SUI女性的安全性，有效性和长期治疗益处。最近发表在《泌尿外科治疗进展》上的一项研究显示，71%的参与者在使用Flyte仅2-12周后就达到了干燥或接近干燥的状态，24小时垫重减轻就证明了这一点。

“Completing this round is an important step in continuing Pelvital’s unwavering dedication to provide women with innovative solutions for pelvic health, including the treatment of SUI,” says Lydia Zeller, President and CEO of Pelvital. “This funding will play a crucial role in accelerating our commercialization of Flyte with a strong emphasis on expanding payor coverage and enhancing clinical education and clinician awareness.”.

Pelvital总裁兼首席执行官莉迪亚·泽勒（LydiaZeller）表示：“完成这一轮是继续Pelvital坚定不移地致力于为女性提供骨盆健康的创新解决方案（包括治疗SUI）的重要一步。”。“这笔资金将在加速Flyte商业化方面发挥关键作用，重点是扩大付款人覆盖范围，增强临床教育和临床医生意识。”